The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Progress Between 2026 And 2030?
The market size for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) has experienced strong growth in recent years. It is projected to expand from $5.97 billion in 2025 to $6.41 billion in 2026, indicating a compound annual growth rate (CAGR) of 7.3%. The growth observed in the past can be attributed to factors such as the limited availability of targeted complement therapies, delayed diagnosis due to the rare nature of these diseases, reliance on plasma exchange and general supportive care, high treatment costs restricting access, and low awareness of complement-mediated disorders.
The market for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) is anticipated to experience robust expansion over the coming years, reaching $8.42 billion by 2030, with a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period is propelled by factors such as the creation of next-generation complement inhibitors, higher diagnosis rates due to advanced testing methods, an increasing emphasis on developing drugs for orphan diseases, broadened reimbursement coverage for rare conditions, and the growing establishment of specialized hematology and nephrology centers. Key developments expected in the forecast period encompass an increasing uptake of complement inhibitor therapies, expanded utilization of genetic and biomarker testing, the emergence of long-acting complement inhibition drugs, the proliferation of specialized rare disease treatment centers, and enhanced early detection of complement-mediated disorders.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24357&type=smp
Which Important Drivers Are Guiding The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Growth?
The growing incidence of rare diseases is anticipated to boost the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in the future. These conditions are defined as medical ailments affecting a minor portion of the populace, usually under 200,000 people, and are frequently marked by intricacy, seriousness, and a requirement for specialized medical care. The increase in rare disease prevalence can be linked to progress in diagnostic tools, facilitating improved detection and recognition of conditions that were previously not reported or identified. Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) play a role in advancing the comprehension and management of rare diseases, offering insights into their underlying mechanisms and potential treatment avenues for conditions where therapeutic choices are scarce. As an illustration, the Food and Drug Administration, a US federal agency, reported that by November 2024, over 7,000 rare diseases had affected more than 30 million individuals across the United States. Consequently, the expanding occurrence of rare diseases is fueling the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market.
How Are Different Segments Classified In The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Segment Analysis?
The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market covered in this report is segmented –
1) By Type: Soliris, Ultomiris
2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria(PNH), Atypical Hemolytic Uremic Syndrome(aHUS)
3) By Treatment Type: Complement Inhibitors, Plasma Exchange Or Infusion, Other Symptomatic Treatments
4) By Diagnosis Method: Clinical Diagnosis, Genetic Testing, Biomarker Testing
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Soliris: Eculizumab For PNH, Eculizumab For aHUS, Eculizumab Biosimilars
2) By Ultomiris: Ravulizumab For PNH, Ravulizumab For aHUS, Ravulizumab Extended-Interval Dosing
What Trends Are Influencing The Evolution Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
Leading companies in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market are prioritizing the creation of novel offerings, such as complement inhibitors, to elevate treatment effectiveness and simplify patient experience. Complement inhibitors represent medicinal agents that obstruct specific elements of the complement system, a segment of the immune system responsible for clearing disease-causing agents and damaged cells. For example, in December 2023, Novartis AG, a pharmaceutical firm headquartered in Switzerland, obtained U.S. Food and Drug Administration (FDA) approval for Fabhalta (iptacopan). This marks the first oral monotherapy designed for adults with paroxysmal nocturnal hemoglobinuria, delivering superior hemoglobin enhancement without requiring transfusions. This groundbreaking complement inhibitor operates by inhibiting Factor B in the alternative complement pathway, ensuring thorough control over both intravascular and extravascular hemolysis. Its oral method of delivery streamlines disease oversight and improves patients’ quality of life, removing the difficulties associated with frequent infusions.
Who Are The Companies Driving Activity In The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market are Roche Holding AG, Alexion Pharmaceuticals Inc, Genentech Inc, Novartis AG, Apellis Pharmaceuticals Inc, Omeros Corporation, BioCryst Pharmaceuticals Inc, ChemoCentryx Inc, Sanofi SA, CSL Behring, Takeda Pharmaceutical Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Horizon Therapeutics, Achillion Pharmaceuticals Inc, Sobi Swedish Orphan Biovitrum AB, ImmunoForge Co Ltd, Care Pharma, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, Mallinckrodt Pharmaceuticals, CANbridge Pharmaceuticals Inc.
Get The Full Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Report:
Which Region Is The Largest In The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market 2026, By The Business Research Company
Hemoglobin Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/hemoglobin-testing-global-market-report
Hemodialysis Market Report
https://www.thebusinessresearchcompany.com/report/hemodialysis-global-market-report
Hemoglobinopathies Treatment Market Report
https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model